Global Mesenchymal Stem Cells Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Mesenchymal Stem Cells Market is presumed to reach the market size of nearly USD 9.93 Billion by 2032 from USD 3.18 Billion in 2023 with a CAGR of 13.5% under the study period 2024 - 2032.

Mesenchymal stem cells, or in short MSCs are a type of versatile adult stem cell present in various bodily tissues such as bone marrow, adipose tissue, and umbilical cord blood. With their remarkable ability to transform into different cell types like bone, cartilage, fat, and muscle cells, MSCs hold immense potential in the fields of regenerative medicine and tissue engineering. Beyond their differentiation capabilities, MSCs also exhibit immunomodulatory characteristics, playing a pivotal role in regulating immune responses and facilitating tissue repair and regeneration processes. This unique combination of traits has positioned them as promising candidates for treating a wide array of medical conditions, such as orthopedic injuries, cardiovascular diseases or autoimmune disorders.

MARKET DYNAMICS

The Mesenchymal Stem Cells (MSCs) market is propelled by several factors shaping the landscape of regenerative medicine and cell therapy. Firstly, the increasing understanding of MSCs' therapeutic potential in tissue repair, immunomodulation, and regenerative medicine drives the demand for MSC-based therapies for various medical conditions, including orthopedic disorders, autoimmune diseases, and neurological disorders. Additionally, the rising prevalence of chronic diseases, aging population, and lifestyle-related ailments fuel the need for innovative treatment modalities with the potential to address unmet medical needs and improve patient outcomes. Moreover, advancements in cell culture techniques, cell isolation methods, and cryopreservation technologies enable the scalable production and clinical translation of MSC-based therapies, driving market expansion and accessibility.

Furthermore, the regulatory approvals and clinical validation of MSC-based products and therapies support market growth and adoption by healthcare providers and patients. Additionally, strategic collaborations, partnerships, and investments among biotechnology companies, academic research institutions, and pharmaceutical companies drive innovation, product development, and commercialization of MSC-based therapies, fostering market growth and competitiveness. Furthermore, increasing investments in clinical research, preclinical studies, and translational medicine initiatives contribute to the expansion of the MSCs market and the development of novel therapeutic applications. However, challenges such as manufacturing scalability, standardization of product quality, and regulatory compliance may hinder the growth of the MSCs market in the next few years, necessitating continued efforts to address these hurdles and unlock the full potential of MSC-based therapies in regenerative medicine and cell therapy.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain Analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mesenchymal stem cells. The growth and trends of the mesenchymal stem cells industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mesenchymal stem cells market report provides detailed data on the segments at the country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product & Services

Products (Cells & Cell Lines, Kits, Media, & Reagents, Others)
Services

By Workflow

Cell Sourcing & Isolation
Culture & Cryopreservation
Differentiation
Characterization

By Type

Autologous
Allogeneic

By Source Of Isolation

Bone Marrow
Cord Blood
Peripheral Blood
Fallopian Tube
Fetal Liver
Lung
Adipose Tissues

By Indication

Bone And Cartilage Repair
Cardiovascular Disease
Inflammatory And Immunological Diseases
Liver Diseases
Cancer
GvHD
Others

By Application

Disease Modelling
Drug Development & Discovery
Stem Cell Banking
Tissue Engineering
Toxicology Studies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Mesenchymal Stem Cells market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Mesenchymal Stem Cells market include Thermo Fisher Scientific Inc., Cell Applications Inc., Axol Biosciences Ltd., Cytori Therapeutics Inc, STEMCELL Technologies, Cyagen Biosciences., Celprogen Inc, BrainStorm Cell Limited., Stemedica Cell Technologies Inc, Merck KGaA (MilliporeSigma), Lonza, PromoCell GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219961

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MESENCHYMAL STEM CELLS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product & Services
- 3.7.2 Market Attractiveness Analysis By Workflow
- 3.7.3 Market Attractiveness Analysis By Type
- 3.7.4 Market Attractiveness Analysis By Source Of Isolation
- 3.7.5 Market Attractiveness Analysis By Indication
- 3.7.6 Market Attractiveness Analysis By Application
- 3.7.7 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY PRODUCT & SERVICES

5.1 Overview by Product & Services
5.2 Historical and Forecast Data
5.3 Analysis by Product & Services
5.4 Products (Cells & Cell Lines, Kits, Media, & Reagents, Others) Historic and Forecast Sales by Regions
5.5 Services Historic and Forecast Sales by Regions

6 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY WORKFLOW

6.1 Overview by Workflow
6.2 Historical and Forecast Data
6.3 Analysis by Workflow
6.4 Cell Sourcing & Isolation Historic and Forecast Sales by Regions
6.5 Culture & Cryopreservation Historic and Forecast Sales by Regions
6.6 Differentiation Historic and Forecast Sales by Regions
6.7 Characterization Historic and Forecast Sales by Regions

7 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY TYPE

7.1 Overview by Type
7.2 Historical and Forecast Data
7.3 Analysis by Type
7.4 Autologous Historic and Forecast Sales by Regions
7.5 Allogeneic Historic and Forecast Sales by Regions

8 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY SOURCE OF ISOLATION

8.1 Overview by Source Of Isolation
8.2 Historical and Forecast Data
8.3 Analysis by Source Of Isolation
8.4 Bone Marrow Historic and Forecast Sales by Regions
8.5 Cord Blood Historic and Forecast Sales by Regions
8.6 Peripheral Blood Historic and Forecast Sales by Regions
8.7 Fallopian Tube Historic and Forecast Sales by Regions
8.8 Fetal Liver Historic and Forecast Sales by Regions
8.9 Lung Historic and Forecast Sales by Regions
8.10. Adipose Tissues Historic and Forecast Sales by Regions

9 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY INDICATION

9.1 Overview by Indication
9.2 Historical and Forecast Data
9.3 Analysis by Indication
9.4 Bone And Cartilage Repair Historic and Forecast Sales by Regions
9.5 Cardiovascular Disease Historic and Forecast Sales by Regions
9.6 Inflammatory And Immunological Diseases Historic and Forecast Sales by Regions
9.7 Liver Diseases Historic and Forecast Sales by Regions
9.8 Cancer Historic and Forecast Sales by Regions
9.9 GvHD Historic and Forecast Sales by Regions
9.10. Others Historic and Forecast Sales by Regions

10 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY APPLICATION

10.1 Overview by Application
10.2 Historical and Forecast Data
10.3 Analysis by Application
10.4 Disease Modelling Historic and Forecast Sales by Regions
10.5 Drug Development & Discovery Historic and Forecast Sales by Regions
10.6 Stem Cell Banking Historic and Forecast Sales by Regions
10.7 Tissue Engineering Historic and Forecast Sales by Regions
10.8 Toxicology Studies Historic and Forecast Sales by Regions
10.9 Others Historic and Forecast Sales by Regions

11 . GLOBAL MESENCHYMAL STEM CELLS MARKET ANALYSIS BY GEOGRAPHY

11.1. Regional Outlook
11.2. Introduction
11.3. North America Sales Analysis
- 11.3.1. Overview, Historic and Forecast Data Sales Analysis
- 11.3.2. North America By Segment Sales Analysis
- 11.3.3. North America By Country Sales Analysis
- 11.3.4. United State Sales Analysis
- 11.3.5. Canada Sales Analysis
- 11.3.6. Mexico Sales Analysis
11.4. Europe Sales Analysis
- 11.4.1. Overview, Historic and Forecast Data Sales Analysis
- 11.4.2. Europe by Segment Sales Analysis
- 11.4.3. Europe by Country Sales Analysis
- 11.4.4. United Kingdom Sales Analysis
- 11.4.5. France Sales Analysis
- 11.4.6. Germany Sales Analysis
- 11.4.7. Italy Sales Analysis
- 11.4.8. Russia Sales Analysis
- 11.4.9. Rest Of Europe Sales Analysis
11.5. Asia Pacific Sales Analysis
- 11.5.1. Overview, Historic and Forecast Data Sales Analysis
- 11.5.2. Asia Pacific by Segment Sales Analysis
- 11.5.3. Asia Pacific by Country Sales Analysis
- 11.5.4. China Sales Analysis
- 11.5.5. India Sales Analysis
- 11.5.6. Japan Sales Analysis
- 11.5.7. South Korea Sales Analysis
- 11.5.8. Australia Sales Analysis
- 11.5.9. Rest Of Asia Pacific Sales Analysis
11.6. Latin America Sales Analysis
- 11.6.1. Overview, Historic and Forecast Data Sales Analysis
- 11.6.2. Latin America by Segment Sales Analysis
- 11.6.3. Latin America by Country Sales Analysis
- 11.6.4. Brazil Sales Analysis
- 11.6.5. Argentina Sales Analysis
- 11.6.6. Peru Sales Analysis
- 11.6.7. Chile Sales Analysis
- 11.6.8. Rest of Latin America Sales Analysis
11.7. Middle East & Africa Sales Analysis
- 11.7.1. Overview, Historic and Forecast Data Sales Analysis
- 11.7.2. Middle East & Africa by Segment Sales Analysis
- 11.7.3. Middle East & Africa by Country Sales Analysis
- 11.7.4. Saudi Arabia Sales Analysis
- 11.7.5. UAE Sales Analysis
- 11.7.6. Israel Sales Analysis
- 11.7.7. South Africa Sales Analysis
- 11.7.8. Rest Of Middle East And Africa Sales Analysis

12 . COMPETITIVE LANDSCAPE OF THE MESENCHYMAL STEM CELLS COMPANIES

12.1. Mesenchymal Stem Cells Market Competition
12.2. Partnership/Collaboration/Agreement
12.3. Merger And Acquisitions
12.4. New Product Launch
12.5. Other Developments

13 . COMPANY PROFILES OF MESENCHYMAL STEM CELLS INDUSTRY

13.1. Company Share Analysis
13.2. Market Concentration Rate
13.3. Thermo Fisher Scientific Inc.
- 13.3.1. Company Overview
- 13.3.2. Company Revenue
- 13.3.3. Products
- 13.3.4. Recent Developments
13.4. Cell Applications Inc.
- 13.4.1. Company Overview
- 13.4.2. Company Revenue
- 13.4.3. Products
- 13.4.4. Recent Developments
13.5. Axol Biosciences Ltd.
- 13.5.1. Company Overview
- 13.5.2. Company Revenue
- 13.5.3. Products
- 13.5.4. Recent Developments
13.6. Cytori Therapeutics Inc
- 13.6.1. Company Overview
- 13.6.2. Company Revenue
- 13.6.3. Products
- 13.6.4. Recent Developments
13.7. STEMCELL Technologies
- 13.7.1. Company Overview
- 13.7.2. Company Revenue
- 13.7.3. Products
- 13.7.4. Recent Developments
13.8. Cyagen Biosciences.
- 13.8.1. Company Overview
- 13.8.2. Company Revenue
- 13.8.3. Products
- 13.8.4. Recent Developments
13.9. Celprogen Inc
- 13.9.1. Company Overview
- 13.9.2. Company Revenue
- 13.9.3. Products
- 13.9.4. Recent Developments
13.10. BrainStorm Cell Limited.
- 13.10.1. Company Overview
- 13.10.2. Company Revenue
- 13.10.3. Products
- 13.10.4. Recent Developments
13.11. Stemedica Cell Technologies Inc
- 13.11.1. Company Overview
- 13.11.2. Company Revenue
- 13.11.3. Products
- 13.11.4. Recent Developments
13.12. Merck KGaA (MilliporeSigma)
- 13.12.1. Company Overview
- 13.12.2. Company Revenue
- 13.12.3. Products
- 13.12.4. Recent Developments
13.13. Lonza
- 13.13.1. Company Overview
- 13.13.2. Company Revenue
- 13.13.3. Products
- 13.13.4. Recent Developments
13.14. PromoCell GmbH
- 13.14.1. Company Overview
- 13.14.2. Company Revenue
- 13.14.3. Products
- 13.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies